Jason Stinnett, MD
Medical Oncology · Layton, UTNPI 1861501694
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Cornerstone Specialty Network LLC at 33.3% of the total. Reporting peaked in 2023 at $697 and has fallen 62.2% since, to $263 in 2025. That places this record below the midpoint for medical oncology clinicians in UT, where the typical reported total is $2,800.
Across 36 payments — averaging $54.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cornerstone Specialty Network LLC$650
- Daiichi Sankyo Inc.$647
- Johnson & Johnson$150
- GSK$94
- Pfizer$61
- Tempus AI, Inc$58
- plus $292 from 13 others
What the payments were for
- Consulting fees$50026%
- Speaking & faculty fees$65033%
- Food & beverage$77039%
- Education$322%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cornerstone Specialty Network LLC | 1 | $650 |
| Daiichi Sankyo Inc. | 5 | $647 |
| Johnson & Johnson | 3 | $150 |
| GSK | 5 | $94 |
| Pfizer | 4 | $61 |
| Tempus AI, Inc | 2 | $58 |
| Lilly USA, LLC | 2 | $48 |
| Genentech, Inc. | 1 | $32 |
| Array Biopharma Inc | 2 | $29 |
| Bristol Myers Squibb | 1 | $28 |
| Genentech USA, Inc. | 1 | $25 |
| Clovis Oncology, Inc. | 2 | $20 |
| AstraZeneca | 1 | $19 |
| Genmab U.S., Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Beigene USA, Inc. | 1 | $16 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| Gilead | 1 | $12 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$500
How this compares
$1,952 in reported general payments places this provider in the 40th percentile of 43 medical oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 59 | $846,960 |
| RevlimidLenalidomide | 41 | $823,731 |
| IbrancePalbociclib | 51 | $788,903 |
| ImbruvicaIbrutinib | 31 | $476,183 |
| JakafiRuxolitinib Phosphate | 27 | $447,329 |
| VenclextaVenetoclax | 24 | $339,152 |
| PomalystPomalidomide | 13 | $299,705 |
| LenvimaLenvatinib Mesylate | 12 | $256,696 |
| ZejulaNiraparib Tosylate | 13 | $223,952 |
| Abiraterone Acetate | 32 | $26,286 |
| XareltoRivaroxaban | 33 | $19,869 |
| EliquisApixaban | 30 | $18,802 |
| Tamoxifen Citrate | 69 | $2,337 |
| Hydroxyurea | 82 | $1,579 |
| Anastrozole | 110 | $1,353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $28 | $823,73141 claims |
| PfizerIbrance, Eliquis | $61 | $807,70481 claims |
| GSKZejula | $94 | $223,95213 claims |
| Johnson & JohnsonXarelto | $150 | $19,86933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 43 medical oncology providers in Utah.
Other medical oncology in Layton
- Bradley HunterSalt Lake City$263K
- William NibleyMurray$160K
- David GillMurray$129K
- Justin CallWest Jordan$106K
- Gregory LittonMurray$99K
- Robert HavardSalt Lake City$57K
- Wallace AkerleySalt Lake City$38K
- Ignacio Garrido-LagunaSalt Lake City$35K
- Mei WeiSalt Lake City$34K
- Xylina GreggSalt Lake City$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.